Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Targeting the PI3-Kinase Pathway in Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dihlmann, S.
Right arrow Articles by Doeberitz, M. v. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dihlmann, S.
Right arrow Articles by Doeberitz, M. v. K.
Vol. 2, 509-516, June 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

Reduction of ß-Catenin/T-Cell Transcription Factor Signaling by Aspirin and Indomethacin Is Caused by an Increased Stabilization of Phosphorylated ß-Catenin

Susanne Dihlmann1, Simone Klein and Magnus von Knebel Doeberitz

Department of Molecular Pathology, Institute of Pathology, University of Heidelberg, D-69120 Heidelberg, Germany

To whom requests for reprints should be addressed, at Division of Molecular Pathology, Department of Pathology, University of Heidelberg, Im Neuenheimer Feld 328, D-69120 Heidelberg, Germany. Phone: 49-6221-56-6119; Fax: 49-6221-56-5773; E-mail: susanne_dihlmann{at}med.uni-heidelberg.de

Constitutive activation of the Wnt/ß-catenin pathway is thought to play a central role in colorectal carcinogenesis. A key output in this pathway is the nuclear level of ß-catenin, which determines the transcription of T-cell transcription factor (TCF)/lymphoid enhancer-binding factor-responsive target genes. In unstimulated cells, ß-catenin is continuously targeted for ubiquitin-dependent degradation, which depends on its NH2-terminal phosphorylation by glycogen synthase kinase-3ß (GSK-3ß) in association with a multiprotein complex. Previously, we have shown that the nonsteroidal anti-inflammatory drugs (NSAIDs) aspirin and indomethacin down-regulate ß-catenin/TCF signaling in colorectal cancer cells. Here, we demonstrate that the reduced signaling activity of ß-catenin in response to NSAIDs is a result of its enhanced phosphorylation. In SW948 and SW480 colorectal cancer cells, phosphorylation of NH2-terminal S/T residues time dependently increased in response to aspirin and indomethacin. In contrast, in 293 cells, NSAID treatment failed to induce detectable levels of ß-catenin phosphorylation but resulted in degradation of ß-catenin within 24 h in serum-deprived cells. The aspirin-induced ß-catenin phosphorylation in colon cancer cells preceded down-regulation of ß-catenin/TCF signaling, suggesting a causal relationship. Inhibition of this process by LiCl pointed to participation of GSK-3ß. Unexpectedly, GSK-3ß was also phosphorylated upon aspirin treatment in six colorectal cancer cell lines. We present evidence that inactivation of a phosphatase rather than stimulation of a kinase or interference with the ubiquitination machinery may be the cause of the stabilized phosphorylation. The data emphasize the importance of ß-catenin in the pathogenesis of colorectal cancer and define it as a key target for anticancer therapeutics.




This article has been cited by other articles:


Home page
Cancer Res.Home page
J. B. Tuynman, L. Vermeulen, E. M. Boon, K. Kemper, A. H. Zwinderman, M. P. Peppelenbosch, and D. J. Richel
Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity and Wnt Activity in Colon Cancer
Cancer Res., February 15, 2008; 68(4): 1213 - 1220.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. H. Choi, M. W. Park, S. Y. Lee, M.-Y. Jeon, M. Y. Kim, H. K. Lee, J. Yu, H.-J. Kim, K. Han, H. Lee, et al.
Intracellular expression of the T-cell factor-1 RNA aptamer as an intramer.
Mol. Cancer Ther., September 1, 2006; 5(9): 2428 - 2434.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. Lu, H. B. Cottam, M. Corr, and D. A. Carson
Repression of {beta}-catenin function in malignant cells by nonsteroidal antiinflammatory drugs
PNAS, December 20, 2005; 102(51): 18567 - 18571.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
C. H. Park, E. R. Hahm, J. H. Lee, K. C. Jung, H. S. Rhee, and C. H. Yang
Ionomycin downregulates {beta}-catenin/Tcf signaling in colon cancer cell line
Carcinogenesis, November 1, 2005; 26(11): 1929 - 1933.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. Dihlmann, M. Kloor, C. Fallsehr, and M. von Knebel Doeberitz
Regulation of AKT1 expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells
Carcinogenesis, September 1, 2005; 26(9): 1503 - 1512.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Fahnert, J. Veijola, G. Roel, M. K. Karkkainen, A. Railo, O. Destree, S. Vainio, and P. Neubauer
Murine Wnt-1 with an Internal c-myc Tag Recombinantly Produced in Escherichia coli Can Induce Intracellular Signaling of the Canonical Wnt Pathway in Eukaryotic Cells
J. Biol. Chem., November 12, 2004; 279(46): 47520 - 47527.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.